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Background
• Current antiretroviral (ARV) formulations necessitate lifelong, daily dosing
• Suboptimal adherence in the clinical setting leads to high risk of treatment failure and 
ranges from 50 to 70 % 
• Additional care and monitoring is necessary in special populations such as paediatric 
patients
• Injectable long-acting nano-formulations could represent a pharmacological option
• NIH funding call has been recently published to highlight the relevance of long-acting 
formulations in infants, children, young adults and pregnant women
Smriti Naswa, Y.S.M., Indian J Sex Transm Dis 32, 1-8 (2011). Chesney, M.A.,Clinical Infectious Diseases, 30(Supplement 2): p. S171-S176 (2000). Spreen, 
W.R., D.A. Margolis, and J.C.J. Pottage,. Curr. Opin. HIV AIDS. 8(6): p. 565-571 (2013). http://grants.nih.gov/grants/guide/notice-files/NOT-HD-16-022.html
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Paediatric patients
• Current paediatric doses are scaled down based on weight from adult dose
• Development of anatomy and physiology is not linear with age
de Wildt, S., et al.,. Clin Pharmacokinet., 1999. 37(6): p. 485-505.
Ginsberg, G., et al., Toxicological Sciences, 2002. 66(2): p. 185-200.
Aims
• Design and validate a paediatric physiologically based pharmacokinetic 
(PBPK) model
• Identify the optimal doses for existing long-acting formulations of 
antiretrovirals according to weight categories of paediatric population
PBPK model
• Physiologically based pharmacokinetic (PBPK) modelling was used to 
inform the optimal dose of ARVs in children and adolescents
 Mathematical description of absorption, distribution, metabolism 
and elimination processes defining pharmacokinetics 
 PBPK modelling integrates in vitro data to simulate drug distribution 
in virtual population 
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Parameter correlation
3.107+(0.012*Weight^1.369))*60 
(5-18 years)
(0.004*Age^2+0.5348*Age+10.92) 
(7-18 years, male)
(271.58+0.163*Age*365)/1000 
(3-18 years, male & female) 
(1.51*BMI-0.7*Age-
3.6+1.4)*Weight/100
(7-18 years, male) 
Population variability
Virtual population
Variability
Essential PBPK Parameters
Volume of distribution
Intramuscular release rate
Metabolic clearance
Pharmacokinetics

Study design
Validation
Prediction
Optimization
• Weights and blood flow rates of children/adolescents at different ages 
• Existing available IM formulations of cabotegravir and rilpivirine in 
adults
• Release rates were kept similar to clinical formulations 
• Pharmacokinetics in children and adolescents according to 
WHO weight categories
• Identify theoretical target dose for once monthly/quarterly administration such that 
the drug plasma concentrations are above the protein binding adjusted IC95 (PAIC95) 
or MEC values
Validation against clinical formulations
[1] Spreen, W., et al., Jaids, 2014. 67(5): p. 487-492.
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Intramuscularly administered cabotegravir (800 mg)
Mean Mean ± SD Clinical
4* PAIC95 - 0.664 µg/ml
AUC - 4,467 vs. 5,257 µg.h/ml
Cmax - 3.3 vs. 3.54 µg/ml
Ctrough - 1.1 vs. 1.2 µg/ml
Release rate – 0.00454 h-1
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Intramuscularly administered rilpivirine (900 mg)
Mean Mean ± SD Clinical
Validation against clinical formulations
AUC - 74,420 vs. 91,087 ng.h/ml
Cmax - 168 vs. 168.7 ng/ml
Ctrough - 79.1 vs. 78.3 ng/ml
Release rate – 0.0009 h-1
[1] Spreen, W., et al., Jaids, 2014. 67(5): p. 487-492.
[1]
MEC – 80 ng/ml
Prediction - Summary
Weight (kg) Rilpivirine (1st and 2nd dose in mg) Cabotegravir (mg)
14 - 19.9 240, 180 960, 720 30 110
20 - 24.9 250, 190 960, 720 30 130
25 - 29.9 250, 190 970, 730 35 150
30 - 34.9 270, 200 980, 740 35 160
35 - 39.9 270, 200 1025, 770 45 170
40 - 44.9 280, 210 1050, 790 45 180
45 - 49.9 290, 220 1075, 810 50 190
50 - 54.9 300, 230 1100, 830 50 200
55 - 59.9 310, 230 1125, 840 55 210
60 - 64.9 310, 230 1150, 860 55 220
65 - 69.9 320, 240 1175, 880 60 240
Duration 4 weeks 12 weeks
Cut-off limit (ng/ml) 20.3 (PAIC95) 80 (MEC) 166 (PAIC95) 664 (4*PAIC95)
Limitations
• The ontogeny and activity of transporters can affect distribution and 
elimination patterns
• Drugs with high lipophilicity tend to diffuse through the lymphatic 
circulation rather than through blood
• Physiological and metabolic variation of muscle composition in children 
compared to adults was not accounted
Dotan, R., et al. (2012). Pediatric exercise science 24(1): 2-21.
Tegenge, M. and R. Mitkus (2013). J. Pharmacokinet. Pharmacodyn. 40(5): 545-556.
Conclusion
• This data could assist in dose optimisation of long-acting intramuscular 
antiretrovirals for paediatric patients improving adherence to therapy
• PBPK modelling represents a predictive tool to improve dosing strategies 
for use in selective population thus potentially simplifying antiretroviral 
therapy
Acknowledgements
• Marco Siccardi 
• Prof. Andrew Owen
• Prof. David Back
• Prof. Saye Khoo
• Prof. Steve Rannard
• Paul Curley
• James Hobson
• Adeniyi Olagunju
• Lee Tatham
• José Moltó
• Catia Marzolini
• Neill Liptrott
• Adny Henrique Silva
• Christopher David
• Darren Michael Moss
• Owain Roberts
• Sharon Murphy
• Christina Chan
• Louise Tidbury
• Justin Chiong
• Rohan Gurjar
• Ana Jiminez-Valverde
• Megan Neary
• Rana Abutaima
• Gini Joshua
• Hannah Kinvig
• Colleagues in the department of 
Molecular and Clinical 
Pharmacology
